196 related articles for article (PubMed ID: 30567902)
1. A Novel, Rapid, and Low-Volume Assay for Therapeutic Drug Monitoring of Posaconazole and Other Long-Chain Azole-Class Antifungal Drugs.
Wiedman GR; Zhao Y; Perlin DS
mSphere; 2018 Dec; 3(6):. PubMed ID: 30567902
[TBL] [Abstract][Full Text] [Related]
2. Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC/MS/MS.
Alffenaar JW; Wessels AM; van Hateren K; Greijdanus B; Kosterink JG; Uges DR
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Jan; 878(1):39-44. PubMed ID: 19945360
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a liquid chromatography-tandem mass spectrometry assay for the simultaneous quantitation of 5 azole antifungals and 1 active metabolite.
McShane AJ; Wang S
Clin Chim Acta; 2017 Nov; 474():8-13. PubMed ID: 28864232
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological considerations for azole antifungal drug management in cystic fibrosis lung transplant patients.
Billaud EM; Guillemain R; Berge M; Amrein C; Lefeuvre S; Louët AL; Boussaud V; Chevalier P
Med Mycol; 2010 Nov; 48 Suppl 1():S52-9. PubMed ID: 21067331
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.
Stott KE; Hope WW
J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i12-i18. PubMed ID: 28355463
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic drug monitoring of systemic antifungal agents: a pragmatic approach for adult and pediatric patients.
John J; Loo A; Mazur S; Walsh TJ
Expert Opin Drug Metab Toxicol; 2019 Nov; 15(11):881-895. PubMed ID: 31550939
[No Abstract] [Full Text] [Related]
7. Pharmacokinetics of Azole Antifungals in Cystic Fibrosis.
Rivosecchi RM; Samanta P; Demehin M; Nguyen MH
Mycopathologia; 2018 Feb; 183(1):139-150. PubMed ID: 28795298
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous quantification of systemic azoles and their major metabolites in human serum by HPLC/PDA: role of azole metabolic rate.
Gomez-Lopez A; Alcazar-Fuoli L; Bernal-Martínez L
Diagn Microbiol Infect Dis; 2018 Sep; 92(1):78-83. PubMed ID: 29778564
[TBL] [Abstract][Full Text] [Related]
9. Advances in antifungal drug measurement by liquid chromatography-mass spectrometry.
Zheng YZ; Wang S
Clin Chim Acta; 2019 Apr; 491():132-145. PubMed ID: 30685359
[TBL] [Abstract][Full Text] [Related]
10. An Aptamer-Based Biosensor for the Azole Class of Antifungal Drugs.
Wiedman GR; Zhao Y; Mustaev A; Ping J; Vishnubhotla R; Johnson ATC; Perlin DS
mSphere; 2017; 2(4):. PubMed ID: 28861519
[TBL] [Abstract][Full Text] [Related]
11. Posaconazole: a new oral antifungal agent with an expanded spectrum of activity.
Morris MI
Am J Health Syst Pharm; 2009 Feb; 66(3):225-36. PubMed ID: 19179636
[TBL] [Abstract][Full Text] [Related]
12. Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations.
Märtson AG; Veringa A; van den Heuvel ER; Bakker M; Touw DJ; van der Werf TS; Span LFR; Alffenaar JC
Mycoses; 2019 Aug; 62(8):698-705. PubMed ID: 31145490
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous determination of seven azole antifungal drugs in serum by ultra-high pressure liquid chromatography and diode array detection.
Mistretta V; Dubois N; Denooz R; Charlier C
Acta Clin Belg; 2014; 69(1):53-61. PubMed ID: 24635400
[TBL] [Abstract][Full Text] [Related]
14. Posaconazole Therapeutic Drug Monitoring in a Regional Hospital Setting.
Lindsay PJ; Bond SE; Norris R; Marriott DJ; Miyakis S
Ther Drug Monit; 2016 Dec; 38(6):804-807. PubMed ID: 27548694
[TBL] [Abstract][Full Text] [Related]
15. Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses.
Tverdek FP; Heo ST; Aitken SL; Granwehr B; Kontoyiannis DP
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28507111
[TBL] [Abstract][Full Text] [Related]
16. Antifungal therapy with azoles and the syndrome of acquired mineralocorticoid excess.
Beck KR; Odermatt A
Mol Cell Endocrinol; 2021 Mar; 524():111168. PubMed ID: 33484741
[TBL] [Abstract][Full Text] [Related]
17. Quantitation of azoles and echinocandins in compartments of peripheral blood by liquid chromatography-tandem mass spectrometry.
Farowski F; Cornely OA; Vehreschild JJ; Hartmann P; Bauer T; Steinbach A; Rüping MJ; Müller C
Antimicrob Agents Chemother; 2010 May; 54(5):1815-9. PubMed ID: 20176892
[TBL] [Abstract][Full Text] [Related]
18. Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis.
Chen L; Wang Y; Zhang T; Li Y; Meng T; Liu L; Hao R; Dong Y
BMC Infect Dis; 2018 Apr; 18(1):155. PubMed ID: 29609553
[TBL] [Abstract][Full Text] [Related]
19. Contribution of a Simple Bioassay in Effective Therapeutic Drug Monitoring of Posaconazole and Voriconazole.
Tonini J; Bailly S; Gautier-Veyret E; Wambergue C; Pelloux H; Thiébaut-Bertrand A; Cornet M; Stanke-Labesque F; Maubon D
Ther Drug Monit; 2015 Oct; 37(5):685-8. PubMed ID: 26384041
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents.
Brüggemann RJ; Alffenaar JW; Blijlevens NM; Billaud EM; Kosterink JG; Verweij PE; Burger DM
Clin Infect Dis; 2009 May; 48(10):1441-58. PubMed ID: 19361301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
